Aspira Women’s Health Announces National Payer Coverage for OvaWatch
<!-- Name:DistributionId Value:8780998 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Aspira
Aspira Women’s Health to Announce Year End 2022 Financial Results and Host Conference…
<!-- Name:DistributionId Value:8781311 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Aspira Women’s Health Announces Preliminary Fourth Quarter 2022 Volume, Preliminary…
Preliminary testing volume during the fourth quarter of 2022 was 5,643, an increase of 18 % compared to the fourth quarter of 2021 Preliminary results consistent with previously…
Aspira Women’s Health Announces Publication of Real-World Data Validating Use of…
Provides clinical validation for the use of OvaWatchSM in the assessment of ovarian cancer risk for suspected benign or indeterminate adnexal masses Paper published in the…
Aspira Women’s Health Announces Three Reimbursement Milestones that Improve Patient…
Expanded Medicare coverage for multi-marker testing, including Ova1Plus® and OvaWatchSM, through the 2023 Omnibus Spending Bill Granted a new PLA Code for OvaWatch by the American…
Aspira Women’s Health Announces the Commercial Launch of OvaWatch(SM)
AUSTIN, Texas, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, announced the…
Aspira Women’s Health Announces Publication of its Second-Generation MultiVariate…
AUSTIN, Texas, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, today announced…
Aspira Women’s Health Hosting Women’s Health Webinar on Ovarian Cancer Risk…
AUSTIN, Texas, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, today announced that…
Aspira Women’s Health Announces Publication of Paper Validating OvaWatch™ Algorithm…
AUSTIN, Texas, June 16, 2022 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, today announced the…
Aspira Women’s Health Announces the Addition of 465,000 Covered Lives Through…
AUSTIN, Texas, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, announced today that it has entered into…